CSL: Our position on AZ-Oxford has not changed

This is a preview of subscriber content

Subscribe now to continue reading.

They restated the company's part in ongoing discussions with AstraZeneca and the government, highlighting the myriad of complexities, including regulatory. They said the company will provide an update when it has one and that it is cognizant of the responsibility to manage the expectations of shareholders and the wider community. …

Subscribe now to continue reading.

CSL: Our position on AZ-Oxford has not changed

This is a preview of subscriber content

Latest Video

Most Read

This exchange on the HTA Review was about as underwhelming as it sounds

Pharmaceutical spending to rise by around $10 billion, but still lose ground to other programs

Australian company reports positive outcome from collaboration

Officials outline ongoing measures to address ADHD medicine shortages

Life sciences industry calls for stronger national strategy to support trials and innovation

New Stories

This exchange on the HTA Review was about as underwhelming as it sounds

AusBiotech unveils international conference program for Australia’s biggest week in biotech

Life sciences industry calls for stronger national strategy to support trials and innovation

Officials outline ongoing measures to address ADHD medicine shortages

Pharmaceutical spending to rise by around $10 billion, but still lose ground to other programs

Australian company reports positive outcome from collaboration

CUREator opens $33 million funding round with CSL and AbbVie partnership

Sign In

CSL: Our position on AZ-Oxford has not changed

This is a preview of subscriber content

Latest Video

Most Read

This exchange on the HTA Review was about as underwhelming as it sounds

Pharmaceutical spending to rise by around $10 billion, but still lose ground to other programs

Australian company reports positive outcome from collaboration

Officials outline ongoing measures to address ADHD medicine shortages

Life sciences industry calls for stronger national strategy to support trials and innovation

Follow Us

New Stories

This exchange on the HTA Review was about as underwhelming as it sounds

AusBiotech unveils international conference program for Australia’s biggest week in biotech

Life sciences industry calls for stronger national strategy to support trials and innovation

Officials outline ongoing measures to address ADHD medicine shortages

Pharmaceutical spending to rise by around $10 billion, but still lose ground to other programs

Australian company reports positive outcome from collaboration

CUREator opens $33 million funding round with CSL and AbbVie partnership